Predicting benefit from anti-angiogenic agents in malignancy

被引：200

作者：

Jubb, Adrian M. ^{[1
]}

Oates, Adam J.

Holden, Scott

Koeppen, Hartmut

机构：

[1] Univ Leeds, Inst Mol Med, Acad Unit Pathol, Leeds LS2 9JT, W Yorkshire, England

[2] St James Hosp, Dept Gen Surg, Leeds LS9 7TF, W Yorkshire, England

来源：

NATURE REVIEWS CANCER | 2006年 / 6卷 / 08期

关键词：

D O I：

10.1038/nrc1946

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

A high probability of benefit is desirable to justify the choice of anti-angiogenic therapy from an ever-expanding list of expensive new anticancer agents. However, biomarkers of response to cytotoxic agents are not optimal for predicting benefit from anti-angiogenic drugs. This discussion will focus on both preclinical and clinical research to identify biomarkers for anti-angiogenic therapies that can inform dosing, early clinical benefit, initial drug choice, emerging resistance and second-line treatments.

引用

页码：626 / 635

页数：10

共 68 条

[1] Role of PIGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1 [J].

Autiero, M ;

Waltenberger, J ;

Communi, D ;

Kranz, A ;

Moons, L ;

Lambrechts, D ;

Kroll, J ;

Plaisance, S ;

De Mol, M ;

Bono, F ;

Kliche, S ;

Fellbrich, G ;

Ballmer-Hofer, K ;

Maglione, D ;

Mayr-Beyrle, U ;

Dewerchin, M ;

Dombrowski, S ;

Stanimirovic, D ;

Van Hummelen, P ;

Dehio, C ;

Hicklin, DJ ;

Persico, G ;

Herbert, JM ;

Communi, D ;

Shibuya, M ;

Collen, D ;

Conway, EM ;

Carmeliet, P .

NATURE MEDICINE, 2003, 9 (07) :936-943

[2] Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis [J].

Bergers, G ;

Brekken, R ;

McMahon, G ;

Vu, TH ;

Itoh, T ;

Tamaki, K ;

Tanzawa, K ;

Thorpe, P ;

Itohara, S ;

Werb, Z ;

Hanahan, D .

NATURE CELL BIOLOGY, 2000, 2 (10) :737-744

[3] Effects of angiogenesis inhibitors on multistage carcinogenesis in mice [J].

Bergers, G ;

Javaherian, K ;

Lo, KM ;

Folkman, J ;

Hanahan, D .

SCIENCE, 1999, 284 (5415) :808-812

[4] Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors [J].

Bergers, G ;

Song, S ;

Meyer-Morse, N ;

Bergsland, E ;

Hanahan, D .

JOURNAL OF CLINICAL INVESTIGATION, 2003, 111 (09) :1287-1295

[5] Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies [J].

Bocci, G ;

Man, S ;

Green, SK ;

Francia, G ;

Ebos, JML ;

du Manoir, JM ;

Weinerman, A ;

Emmenegger, U ;

Ma, L ;

Thorpe, P ;

Davidoff, A ;

Huber, J ;

Hicklin, DJ ;

Kerbel, RS .

CANCER RESEARCH, 2004, 64 (18) :6616-6625

[6] Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions [J].

Carmeliet, P ;

Moons, L ;

Luttun, A ;

Vincenti, V ;

Compernolle, V ;

De Mol, M ;

Wu, Y ;

Bon, F ;

Devy, L ;

Beck, H ;

Scholz, D ;

Acker, T ;

DiPalma, T ;

Dewerchin, M ;

Noel, A ;

Stalmans, I ;

Barra, A ;

Blacher, S ;

Vandendriessche, T ;

Ponten, A ;

Eriksson, U ;

Plate, KH ;

Foidart, JM ;

Schaper, W ;

Charnock-Jones, DS ;

Hicklin, DJ ;

Herbert, JM ;

Collen, D ;

Persico, MG .

NATURE MEDICINE, 2001, 7 (05) :575-583

[7] Angiogenesis in cancer and other diseases [J].

Carmeliet, P ;

Jain, RK .

NATURE, 2000, 407 (6801) :249-257

[8] Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors [J].

Casanovas, O ;

Hicklin, DJ ;

Bergers, G ;

Hanahan, D .

CANCER CELL, 2005, 8 (04) :299-309

[9]

Christensen O, 2005, EUR J CLIN PHARMACOL, V61, P704

[10] VASCULAR ENDOTHELIAL GROWTH-FACTOR AND ITS RECEPTORS, FLT-1 AND FLK-1, ARE EXPRESSED IN NORMAL PANCREATIC-ISLETS AND THROUGHOUT ISLET-CELL TUMORIGENESIS [J].

CHRISTOFORI, G ;

NAIK, P ;

HANAHAN, D .

MOLECULAR ENDOCRINOLOGY, 1995, 9 (12) :1760-1770

← 1 2 3 4 5 6 7 →